Sotagliflozin Hail Mary? Lexicon Seeks Opportunity For Formal Hearing On FDA Intent To Deny Approval

After complete response letter, Lexicon triggers rarely used mechanism for formal hearing, prompting US FDA to publicly list its problems with the proposed type 1 diabetes drug, for which Sanofi had originally sought approval.

Dispute (lolloj/Shutterstock.com)
US FDA denied two formal requests for dispute resolution related to sotagliflozin after issuing a complete response letter to original application holder Sanofi . • Source: Shutterstock

More from US FDA

More from Agency Leadership